1
|
Wang P, Zhu Y, Jia X, Ying X, Sun L, Ruan S. Clinical prognostic value of OSGIN2 in gastric cancer and its proliferative effect in vitro. Sci Rep 2023; 13:5775. [PMID: 37031243 PMCID: PMC10082810 DOI: 10.1038/s41598-023-32934-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Accepted: 04/04/2023] [Indexed: 04/10/2023] Open
Abstract
This study explored the promoting effect of oxidative stress-induced growth inhibitor family member 2(OSGIN2) on gastric cancer (GC) through public databases and in vitro experiments. The potential relationship between OSGIN2 expression, prognosis, functional enrichment of associated differential genes, immune infiltration, and mutational information in gastric cancer were comprehensively investigated using bioinformatics analysis. OSGIN2 was knocked down using small interfering RNA (siRNA) transfection for subsequent cell function testing. The results showed that gastric carcinoma cells and tissues contained high levels of OSGIN2, which was associated with a poor prognosis for GC patients. It was important in the cell cycle, autophagy, etc., and was related to a variety of tumor-related signal pathways. Knockdown of OSGIN2 inhibited tumor cell proliferation and contributed to cell cycle arrest. It was also correlated with tumor immune infiltrating cells (TILs), affecting antitumor immune function. Our analysis highlights that OSING2, as a new biomarker, has diagnostic and prognostic value in gastric cancer and is a potentially effective target in GC treatment.
Collapse
Affiliation(s)
- Peipei Wang
- Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, China
- Zhejiang Key Lab of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer, Zhejiang Cancer Hospital, Hangzhou, 310022, China
| | - Ying Zhu
- Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, China
| | - Xinru Jia
- The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Xiangchang Ying
- The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, 310053, China
| | - Leitao Sun
- Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, China.
- Academy of Chinese Medical Science, Zhejiang Chinese Medical University, Hangzhou, 310053, China.
| | - Shanming Ruan
- Department of Medical Oncology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, 310006, China.
| |
Collapse
|
2
|
Gorska-Ponikowska M, Bastian P, Zauszkiewicz-Pawlak A, Ploska A, Zubrzycki A, Kuban-Jankowska A, Nussberger S, Kalinowski L, Kmiec Z. Regulation of mitochondrial dynamics in 2-methoxyestradiol-mediated osteosarcoma cell death. Sci Rep 2021; 11:1616. [PMID: 33452331 PMCID: PMC7811003 DOI: 10.1038/s41598-020-80816-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Accepted: 12/28/2020] [Indexed: 01/29/2023] Open
Abstract
Osteosarcoma (OS) is one of the most malignant tumors of childhood and adolescence. Research on mitochondrial dynamics (fusion/fission) and biogenesis has received much attention in last few years, as they are crucial for death of cancer cells. Specifically, it was shown that increased expression of the cytoplasmic dynamin-related protein 1 (Drp1) triggers mitochondrial fission (division), which activates BAX and downstream intrinsic apoptosis, effectively inhibiting OS growth. In the presented study, human OS cells (metastatic 143B OS cell line) were incubated with 2-methoxyestradiol (2-ME) at both physiologically and pharmacologically relevant concentrations. Cell viability was determined by the MTT assay. Confocal microscopy and western blot methods were applied to examine changes in Drp1 and BAX protein levels. Mitochondrial Division Inhibitor 1, MDIVI-1, was used in the study to further examine the role of Drp1 in 2-ME-mediated mechanism of action. To determine quantitative and qualitative changes in mitochondria, electron microscopy was used. 2-ME at all used concentrations increased mitochondrial fission and induced autophagy in OS cells. At the concentration of 1 µM 2-ME increased the area density of mitochondria in OS cells. Subsequent, upregulated expression of Drp1 and BAX proteins by 2-ME strongly suggests the activation of the intrinsic apoptosis pathway. We further observed 2-ME-mediated regulation of glycolytic state of OS cells. Therefore, we suggest that changes of mitochondrial dynamics may represent a novel mechanism of anticancer action of 2-ME. This finding may open new approaches to improve the efficacy of chemotherapy in the treatment of OS, however, it has to be confirmed by in vivo studies.
Collapse
Affiliation(s)
- Magdalena Gorska-Ponikowska
- grid.11451.300000 0001 0531 3426Department of Medical Chemistry, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland ,grid.5719.a0000 0004 1936 9713Department of Biophysics, Institute of Biomaterials and Biomolecular Systems, University of Stuttgart, Stuttgart, Germany ,grid.428936.2Euro-Mediterranean Institute of Science and Technology, Palermo, Italy
| | - Paulina Bastian
- grid.11451.300000 0001 0531 3426Department of Medical Chemistry, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland
| | - Agata Zauszkiewicz-Pawlak
- grid.11451.300000 0001 0531 3426Department of Histology, Medical University of Gdansk, Gdansk, Poland
| | - Agata Ploska
- grid.11451.300000 0001 0531 3426Department of Medical Laboratory Diagnostics, Medical University of Gdansk, Gdansk, Poland ,Biobanking and Biomolecular Resources Research Infrastructure Poland (BBMRI.PL), Gdansk, Poland
| | - Adrian Zubrzycki
- grid.11451.300000 0001 0531 3426Department of Histology, Medical University of Gdansk, Gdansk, Poland
| | - Alicja Kuban-Jankowska
- grid.11451.300000 0001 0531 3426Department of Medical Chemistry, Medical University of Gdansk, Debinki 1, 80-211 Gdansk, Poland
| | - Stephan Nussberger
- grid.5719.a0000 0004 1936 9713Department of Biophysics, Institute of Biomaterials and Biomolecular Systems, University of Stuttgart, Stuttgart, Germany
| | - Leszek Kalinowski
- grid.11451.300000 0001 0531 3426Department of Medical Laboratory Diagnostics, Medical University of Gdansk, Gdansk, Poland ,Biobanking and Biomolecular Resources Research Infrastructure Poland (BBMRI.PL), Gdansk, Poland
| | - Zbigniew Kmiec
- grid.11451.300000 0001 0531 3426Department of Histology, Medical University of Gdansk, Gdansk, Poland
| |
Collapse
|
3
|
Mori MP, Souza-Pinto NCD. PPRC1, but not PGC-1α, levels directly correlate with expression of mitochondrial proteins in human dermal fibroblasts. Genet Mol Biol 2020; 43:e20190083. [PMID: 32639509 PMCID: PMC7341727 DOI: 10.1590/1678-4685-gmb-2019-0083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 04/15/2020] [Indexed: 11/22/2022] Open
Abstract
The XPC protein, which is mutated in xeroderma pigmentosum (XP) complementation group C (XP-C), is a lesion recognition factor in NER, but it has also been shown to interact with and stimulate DNA glycosylases, to act as transcriptional co-activator and on energy metabolism adaptation. We have previously demonstrated that XP-C cells show increased mitochondrial H2O2 production with a shift between respiratory complexes I and II, leading to sensitivity to mitochondrial stress. Here we report a marked decrease in expression of the transcriptional co-activator PGC-1α, a master regulator of mitochondrial biogenesis, in XP-C cells. A transcriptional role for XPC in PGC-1α expression was discarded, as XPC knockdown did not downregulate PGC-1α expression and XPC-corrected cells still showed lower PGC-1α expression. DNA methylation alone did not explain PGC-1α silencing. In four different XP-C cell lines tested, reduction of PGC-1α expression was detected in three, all of them carrying the c.1643_1644delTG mutation (ΔTG) in XPC. Indeed, all cell lines carrying XPC ΔTG mutation, whether homozygous or heterozygous, presented decreased PGC-1α expression. However, this alteration in gene expression was not exclusive to XPC ΔTG cell lines, for other non-related cell lines also showed altered PGC-1α expression. Moreover, PGC1-α expression did not correlate with expression levels of TFAM and SDHA, known PGC-1α target-genes. In turn, PPRC1, another member of the PGC family of transcription co-activators controlling mitochondrial biogenesis, displayed a good correlation between its expression in 10 cell lines and TFAM and SDHA. Nonetheless, PGC-1α knockdown led to a slight decrease of its target-gene protein level, TFAM, and subsequently of a mtDNA-encoded gene, MT-CO2. These results indicate that PGC-1α and PPRC1 cooperate as regulators of mitochondrial biogenesis and maintenance in fibroblasts.
Collapse
Affiliation(s)
- Mateus Prates Mori
- Universidade de São Paulo, Departamento de Bioquímica, Instituto de Química, São Paulo, SP, Brazil
| | | |
Collapse
|
4
|
Gorska-Ponikowska M, Kuban-Jankowska A, Eisler SA, Perricone U, Lo Bosco G, Barone G, Nussberger S. 2-Methoxyestradiol Affects Mitochondrial Biogenesis Pathway and Succinate Dehydrogenase Complex Flavoprotein Subunit A in Osteosarcoma Cancer Cells. Cancer Genomics Proteomics 2018; 15:73-89. [PMID: 29275365 DOI: 10.21873/cgp.20067] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2017] [Revised: 11/19/2017] [Accepted: 11/29/2017] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND/AIM Dysregulation of mitochondrial pathways is implicated in several diseases, including cancer. Notably, mitochondrial respiration and mitochondrial biogenesis are favored in some invasive cancer cells, such as osteosarcoma. Hence, the aim of the current work was to investigate the effects of 2-methoxyestradiol (2-ME), a potent anticancer agent, on the mitochondrial biogenesis of osteosarcoma cells. MATERIALS AND METHODS Highly metastatic osteosarcoma 143B cells were treated with 2-ME separately or in combination with L-lactate, or with the solvent (non-treated control cells). Protein levels of α-syntrophin and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC-1α) were determined by western blotting. Impact of 2-ME on mitochondrial mass, regulation of cytochrome c oxidase I (COXI) expression, and succinate dehydrogenase complex flavoprotein subunit A (SDHA) was determined by immunofluorescence analyses. Inhibition of sirtuin 3 (SIRT3) activity by 2-ME was investigated by fluorescence assay and also, using molecular docking and molecular dynamics simulations. RESULTS L-lactate induced mitochondrial biogenesis pathway via up-regulation of COXI. 2-ME inhibited mitochondrial biogenesis via regulation of PGC-1α, COXI, and SIRT3 in a concentration-dependent manner as a consequence of nuclear recruitment of neuronal nitric oxide synthase and nitric oxide generation. It was also proved that 2-ME inhibited SIRT3 activity by binding to both the canonical and allosteric inhibitor binding sites. Moreover, regardless of the mitochondrial biogenesis pathway, 2-ME affected the expression of SDHA. CONCLUSION Herein, mitochondrial biogenesis pathway regulation and SDHA were presented as novel targets of 2-ME, and moreover, 2-ME was demonstrated as a potent inhibitor of SIRT3. L-lactate was confirmed to exert pro-carcinogenic effects on osteosarcoma cells via the induction of the mitochondrial biogenesis pathway. Thus, L-lactate level may be considered as a prognostic biomarker for osteosarcoma.
Collapse
Affiliation(s)
- Magdalena Gorska-Ponikowska
- Department of Medical Chemistry, Medical University of Gdansk, Gdansk, Poland .,Department of Biophysics, Institute of Biomaterials and Biomolecular Systems, University of Stuttgart, Stuttgart, Germany
| | | | - Stephan A Eisler
- Stuttgart Research Center Systems Biology, University of Stuttgart, Stuttgart, Germany
| | | | - Giosuè Lo Bosco
- Department of Mathematics and Computer Science, Università degli Studi di Palermo, Palermo, Italy.,Euro-Mediterranean Institute of Science and Technology, Palermo, Italy
| | - Giampaolo Barone
- Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, Università degli Studi di Palermo, Palermo, Italy
| | - Stephan Nussberger
- Department of Biophysics, Institute of Biomaterials and Biomolecular Systems, University of Stuttgart, Stuttgart, Germany
| |
Collapse
|
5
|
Wei Y, Chen L, Xu H, Xie C, Zhou Y, Zhou F. Mitochondrial Dysfunctions Regulated Radioresistance through Mitochondria-to-Nucleus Retrograde Signaling Pathway of NF-κB/PI3K/AKT2/mTOR. Radiat Res 2018; 190:204-215. [PMID: 29863983 DOI: 10.1667/rr15021.1] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
We investigated the relationship between significantly different genes of the mitochondria-to-nucleus retrograde signaling pathway (RTG) in H1299 ρ0 cells (mtDNA depleted cell) and compared their radiosensitivity to that of parental ρ+ cells, to determine the possible intervention targets of radiosensitization. ρ0 cells were depleted of mitochondrial DNA by chronic culturing in ethidium bromide at low concentration. Radiosensitivity was analyzed using clonogenic assay. Western blot was used to analyze the cell cycle-related proteins, serine/threonine kinase ataxia telangiectasia mutant (ATM), ataxia telangiectasia and Rad3-related protein (ATR) and cyclin B1 (CCNB1). The γ-H2AX foci were detected using confocal fluorescence microscopy. RNA samples were hybridized using the Agilent human genome expression microarray. The Kyoto Encyclopedia of Genes and Genomes (KEGG) database was used for Gene Ontology (GO) Consortium and pathway annotations of differentially expressed genes, respectively. The H1299 ρ0 cells were found to be more radioresistant than ρ+ cells. The ATP production of H1299 ρ0 cells was lower than that of the ρ+ cells before or after irradiation. Both H1299 ρ0 and ρ+ cells had higher ROS levels after irradiation, however, the radiation-induced ROS production in ρ0 cells was significantly lower than in ρ+ cells. In addition, the percentage of apoptosis in H1299 ρ0 cells was lower than in ρ+ cells after 6 Gy irradiation. As for the cell cycle and DNA damage response-related proteins ATM, ATR and CCNB1, the expression levels in ρ0 cells were significantly higher than in ρ+ cells, and there were less γ-H2AX foci in the ρ0 than ρ+ cells after irradiation. Furthermore, the results of the human genome expression microarray demonstrated that the phosphorylated protein levels of the NF-κB/PI3K/AKT2/mTOR signaling pathway were increased after 6 Gy irradiation and were decreased after treatment with the AKT2-specific inhibitor MK-2206 combined with radiation in H1299 ρ0 cells. MK-2206 treatment also led to an increase in pro-apoptotic proteins. In conclusion, these results demonstrate that mtDNA depletion might activate the mitochondria-to-nucleus retrograde signaling pathway of NF-κB/PI3K/AKT2/mTOR and induce radioresistance in H1299 ρ0 cells by evoking mitochondrial dysfunctions.
Collapse
Affiliation(s)
- Yuehua Wei
- a Department of Radiation and Medical Oncology.,b Hubei Key Laboratory of Tumor Biological Behaviors.,d Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China
| | - Lulu Chen
- a Department of Radiation and Medical Oncology.,b Hubei Key Laboratory of Tumor Biological Behaviors.,c Hubei Clinical Cancer Study Centre, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China.,d Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China
| | - Hui Xu
- a Department of Radiation and Medical Oncology.,b Hubei Key Laboratory of Tumor Biological Behaviors.,c Hubei Clinical Cancer Study Centre, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Conghua Xie
- a Department of Radiation and Medical Oncology.,b Hubei Key Laboratory of Tumor Biological Behaviors.,c Hubei Clinical Cancer Study Centre, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Yunfeng Zhou
- a Department of Radiation and Medical Oncology.,b Hubei Key Laboratory of Tumor Biological Behaviors.,c Hubei Clinical Cancer Study Centre, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| | - Fuxiang Zhou
- a Department of Radiation and Medical Oncology.,b Hubei Key Laboratory of Tumor Biological Behaviors.,c Hubei Clinical Cancer Study Centre, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
| |
Collapse
|
6
|
Dumont S, Le Pennec S, Donnart A, Teusan R, Steenman M, Chevalier C, Houlgatte R, Savagner F. Transcriptional orchestration of mitochondrial homeostasis in a cellular model of PGC-1-related coactivator-dependent thyroid tumor. Oncotarget 2018; 9:15883-15894. [PMID: 29662614 PMCID: PMC5882305 DOI: 10.18632/oncotarget.24633] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2017] [Accepted: 02/26/2018] [Indexed: 12/03/2022] Open
Abstract
The PGC-1 (Peroxisome proliferator-activated receptor Gamma Coactivator-1) family of coactivators (PGC-1α, PGC-1β, and PRC) plays a central role in the transcriptional control of mitochondrial biogenesis and oxidative phosphorylation (OXPHOS) processes. These coactivators integrate mitochondrial energy production into cell metabolism using complementary pathways. The XTC.UC1 cell line is a mitochondria-rich model of thyroid tumors whose biogenesis is almost exclusively dependent on PRC. Here we aim to propose an integrative view of the cellular pathways regulated by PRC through integration of cDNA and miRNA microarray data and chromatin immunoprecipitation results obtained from XTC.UC1 cells invalidated for PRC. This study showes that PRC induces a complex network of cellular functions interacting with at least one to five of the studied transcription factors (Estrogen Related Receptor alpha, ERR1; Nuclear-Respiratory Factors, NRF1 and NRF2; cAMP Response Element Binding, CREB; and Ying Yang, YY1). Our data confirm that ERR1 is a key partner of PRC in the regulation of mitochondrial functions and suggest a potential role of this complex in RNA processing. PRC is also involved in transcriptional regulatory complexes targeting 12 miRNAs, five of which are involved in the control of the OXPHOS process. Our findings demonstrate that the PRC coactivator can act in complex with several transcription factors and regulate miRNA expression to control the fine regulation of main metabolic functions in the cell. Therefore, in PGC-1α/β-associated pathologies, PRC, as a metabolic sensor, may ensure mitochondrial homeostasis.
Collapse
Affiliation(s)
- Solenne Dumont
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, BP 70721, 44007 NANTES Cedex 1, France
| | | | - Audrey Donnart
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, BP 70721, 44007 NANTES Cedex 1, France
| | - Raluca Teusan
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, BP 70721, 44007 NANTES Cedex 1, France
| | - Marja Steenman
- L'institut du Thorax, INSERM, CNRS, UNIV Nantes, BP 70721, 44007 NANTES Cedex 1, France
| | | | - Rémi Houlgatte
- Inserm UMR 954, Faculté de Médecine, BP 184, 54505 VANDOEUVRE-LÈS-NANCY Cedex, France
| | | |
Collapse
|
7
|
Yi HS, Chang JY, Kim KS, Shong M. Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer. Korean J Intern Med 2017; 32:780-789. [PMID: 28823142 PMCID: PMC5583459 DOI: 10.3904/kjim.2016.420] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2016] [Accepted: 03/07/2017] [Indexed: 02/02/2023] Open
Abstract
Thyroid cancer is one of the most common malignancies of endocrine organs, and its incidence rate has increased steadily over the past several decades. Most differentiated thyroid tumors derived from thyroid epithelial cells exhibit slow-growing cancers, and patients with these tumors can achieve a good prognosis with surgical removal and radioiodine treatment. However, a small proportion of patients present with advanced thyroid cancer and are unusually resistant to current drug treatment modalities. Thyroid tumorigenesis is a complex process that is regulated by the activation of oncogenes, inactivation of tumor suppressors, and alterations in programmed cell death. Mitochondria play an essential role during tumor formation, progression, and metastasis of thyroid cancer. Recent studies have successfully observed the mitochondrial etiology of thyroid carcinogenesis. This review focuses on the recent progress in understanding the molecular mechanisms of thyroid cancer relating to altered mitochondrial metabolism.
Collapse
Affiliation(s)
- Hyon-Seung Yi
- Research Center for Endocrine and Metabolic Diseases, Chungnam National University School of Medicine, Daejeon, Korea
| | - Joon Young Chang
- Research Center for Endocrine and Metabolic Diseases, Chungnam National University School of Medicine, Daejeon, Korea
- Department of Medical Science, Chungnam National University School of Medicine, Daejeon, Korea
| | - Koon Soon Kim
- Research Center for Endocrine and Metabolic Diseases, Chungnam National University School of Medicine, Daejeon, Korea
| | - Minho Shong
- Research Center for Endocrine and Metabolic Diseases, Chungnam National University School of Medicine, Daejeon, Korea
- Correspondence to Minho Shong, M.D. Research Center for Endocrine and Metabolic Diseases, Chungnam National University School of Medicine, 266 Munhwa-ro, Jung-gu, Daejeon 35015, Korea Tel: +82-42-280-6994 Fax: +82-42-280-7995 E-mail:
| |
Collapse
|
8
|
Tengan CH, Moraes CT. NO control of mitochondrial function in normal and transformed cells. BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGETICS 2017; 1858:573-581. [PMID: 28216426 PMCID: PMC5487294 DOI: 10.1016/j.bbabio.2017.02.009] [Citation(s) in RCA: 56] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 01/19/2017] [Accepted: 02/15/2017] [Indexed: 10/25/2022]
Abstract
Nitric oxide (NO) is a signaling molecule with multiple facets and involved in numerous pathological process, including cancer. Among the different pathways where NO has a functionally relevant participation, is the control of mitochondrial respiration and biogenesis. NO is able to inhibit the electron transport chain, mainly at Complex IV, regulating oxygen consumption and ATP generation, but at the same time, can also induce increase in reactive oxygen and nitrogen species. The presence of reactive species can induce oxidative damage or participate in redox signaling. In this review, we discuss how NO affects mitochondrial respiration and mitochondrial biogenesis, and how it influences the development of mitochondrial deficiency and cancer. This article is part of a Special Issue entitled Mitochondria in Cancer, edited by Giuseppe Gasparre, Rodrigue Rossignol and Pierre Sonveaux.
Collapse
Affiliation(s)
- Celia H Tengan
- Department of Neurology and Neurosurgery, Escola Paulista de Medicina, Universidade Federal de São Paulo, R. Pedro de Toledo, 781, setimo andar, frente, 04039-032, São Paulo, SP, Brazil.
| | - Carlos T Moraes
- University of Miami Miller School of Medicine, Dept. of Neurology and Cell Biology, 1420 NW 9th Avenue, Rm.229, Miami, FL 33136, USA.
| |
Collapse
|
9
|
Saki M, Prakash A. DNA damage related crosstalk between the nucleus and mitochondria. Free Radic Biol Med 2017; 107:216-227. [PMID: 27915046 PMCID: PMC5449269 DOI: 10.1016/j.freeradbiomed.2016.11.050] [Citation(s) in RCA: 90] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2016] [Revised: 10/25/2016] [Accepted: 11/29/2016] [Indexed: 12/18/2022]
Abstract
The electron transport chain is the primary pathway by which a cell generates energy in the form of ATP. Byproducts of this process produce reactive oxygen species that can cause damage to mitochondrial DNA. If not properly repaired, the accumulation of DNA damage can lead to mitochondrial dysfunction linked to several human disorders including neurodegenerative diseases and cancer. Mitochondria are able to combat oxidative DNA damage via repair mechanisms that are analogous to those found in the nucleus. Of the repair pathways currently reported in the mitochondria, the base excision repair pathway is the most comprehensively described. Proteins that are involved with the maintenance of mtDNA are encoded by nuclear genes and translocate to the mitochondria making signaling between the nucleus and mitochondria imperative. In this review, we discuss the current understanding of mitochondrial DNA repair mechanisms and also highlight the sensors and signaling pathways that mediate crosstalk between the nucleus and mitochondria in the event of mitochondrial stress.
Collapse
Affiliation(s)
- Mohammad Saki
- Mitchell Cancer Institute, The University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36604, United States
| | - Aishwarya Prakash
- Mitchell Cancer Institute, The University of South Alabama, 1660 Springhill Avenue, Mobile, AL 36604, United States.
| |
Collapse
|
10
|
Keßler J, Rot S, Bache M, Kappler M, Würl P, Vordermark D, Taubert H, Greither T. miR-199a-5p regulates HIF-1α and OSGIN2 and its expression is correlated to soft-tissue sarcoma patients' outcome. Oncol Lett 2016; 12:5281-5288. [PMID: 28101243 DOI: 10.3892/ol.2016.5320] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Accepted: 08/10/2016] [Indexed: 12/18/2022] Open
Abstract
Soft tissue sarcomas are a heterogeneous group of malignant neoplasms of mesenchymal origin. Partly due to hypoxia, an aggressive and radioresistant phenotype frequently develops, resulting in poorer patient outcome. microRNAs (miRNAs) are tiny, non-coding regulators of gene expression and in situations of cellular stress situations may predict clinical progression and patient outcome. In the present study, hypoxia-associated miR-199a-5p expression in 96 soft tissue sarcoma samples was analysed by reverse transcription-quantitative polymerase chain reaction and associations between miR-199a-5p expression and patient clinicopathological characteristics and survival were measured. Additionally, luciferase reporter assays analyzed the post-transcriptional regulation of hypoxia-associated genes hypoxia-inducible factor 1α (HIF-1α), oxidative stress induced growth inhibitor 2 (OSGIN2) and vascular endothelial growth factor (VEGF) by miR-199a-5p. Survival analyses indicated that low expression of miR-199a-5p was significantly correlated with poorer tumor-specific survival (univariate Cox's-Regression analyses; relative risk=1.92, P=0.029). Furthermore, it was demonstrated that the 3'UTR of HIF-1α and OSGIN2 genes were regulated by miR-199a-5p in-vitro, although the 3'UTR of VEGF was not. To the best of our knowledge, this is the first report demonstrating the regulation of the 3'untranslated region of the OSGIN2 gene by miR-199a-5p and a significant correlation between low miR-199a-5p expression and a poor outcome of patients with soft tissue sarcoma.
Collapse
Affiliation(s)
- Jacqueline Keßler
- Department of Radiotherapy, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Swetlana Rot
- Department of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Matthias Bache
- Department of Radiotherapy, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Matthias Kappler
- Department of Oral and Maxillofacial Plastic Surgery, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Peter Würl
- Department of General and Visceral Surgery, Diakonie Hospital, D-06114 Halle (Saale), Germany
| | - Dirk Vordermark
- Department of Radiotherapy, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| | - Helge Taubert
- Clinic of Urology, FA University Hospital Erlangen-Nürnberg, D-91052 Erlangen, Germany
| | - Thomas Greither
- Center for Reproductive Medicine and Andrology, Martin Luther University Halle-Wittenberg, D-06120 Halle (Saale), Germany
| |
Collapse
|
11
|
Stimulatory effect of CSE-generated H2S on hepatic mitochondrial biogenesis and the underlying mechanisms. Nitric Oxide 2016; 58:67-76. [DOI: 10.1016/j.niox.2016.06.005] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2016] [Accepted: 06/21/2016] [Indexed: 12/19/2022]
|
12
|
Caneba CA, Yang L, Baddour J, Curtis R, Win J, Hartig S, Marini J, Nagrath D. Nitric oxide is a positive regulator of the Warburg effect in ovarian cancer cells. Cell Death Dis 2014; 5:e1302. [PMID: 24967964 PMCID: PMC4611736 DOI: 10.1038/cddis.2014.264] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2014] [Revised: 05/14/2014] [Accepted: 05/16/2014] [Indexed: 01/25/2023]
Abstract
Ovarian cancer (OVCA) is among the most lethal gynecological cancers leading to high mortality rates among women. Increasing evidence indicate that cancer cells undergo metabolic transformation during tumorigenesis and growth through nutrients and growth factors available in tumor microenvironment. This altered metabolic rewiring further enhances tumor progression. Recent studies have begun to unravel the role of amino acids in the tumor microenvironment on the proliferation of cancer cells. One critically important, yet often overlooked, component to tumor growth is the metabolic reprogramming of nitric oxide (NO) pathways in cancer cells. Multiple lines of evidence support the link between NO and tumor growth in some cancers, including pancreas, breast and ovarian. However, the multifaceted role of NO in the metabolism of OVCA is unclear and direct demonstration of NO's role in modulating OVCA cells' metabolism is lacking. This study aims at indentifying the mechanistic links between NO and OVCA metabolism. We uncover a role of NO in modulating OVCA metabolism: NO positively regulates the Warburg effect, which postulates increased glycolysis along with reduced mitochondrial activity under aerobic conditions in cancer cells. Through both NO synthesis inhibition (using L-arginine deprivation, arginine is a substrate for NO synthase (NOS), which catalyzes NO synthesis; using L-Name, a NOS inhibitor) and NO donor (using DETA-NONOate) analysis, we show that NO not only positively regulates tumor growth but also inhibits mitochondrial respiration in OVCA cells, shifting these cells towards glycolysis to maintain their ATP production. Additionally, NO led to an increase in TCA cycle flux and glutaminolysis, suggesting that NO decreases ROS levels by increasing NADPH and glutathione levels. Our results place NO as a central player in the metabolism of OVCA cells. Understanding the effects of NO on cancer cell metabolism can lead to the development of NO targeting drugs for OVCAs.
Collapse
Affiliation(s)
- C A Caneba
- 1] Laboratory for Systems Biology of Human Diseases, Rice University, Houston, TX, USA [2] Department of Bioengineering, Rice University, Houston, TX, USA
| | - L Yang
- 1] Laboratory for Systems Biology of Human Diseases, Rice University, Houston, TX, USA [2] Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX, USA
| | - J Baddour
- 1] Laboratory for Systems Biology of Human Diseases, Rice University, Houston, TX, USA [2] Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX, USA
| | - R Curtis
- 1] Laboratory for Systems Biology of Human Diseases, Rice University, Houston, TX, USA [2] Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX, USA
| | - J Win
- 1] Laboratory for Systems Biology of Human Diseases, Rice University, Houston, TX, USA [2] Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX, USA
| | - S Hartig
- Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - J Marini
- 1] Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA [2] Pediatric Critical Care Medicine and USDA/ARS Children's Nutrition Research Center, Baylor College of Medicine, Houston, TX, USA
| | - D Nagrath
- 1] Laboratory for Systems Biology of Human Diseases, Rice University, Houston, TX, USA [2] Department of Bioengineering, Rice University, Houston, TX, USA [3] Department of Chemical and Biomolecular Engineering, Rice University, Houston, TX, USA
| |
Collapse
|
13
|
Rivalin R, Lepinoux-Chambaud C, Eyer J, Savagner F. The NFL-TBS.40-63 anti-glioblastoma peptide disrupts microtubule and mitochondrial networks in the T98G glioma cell line. PLoS One 2014; 9:e98473. [PMID: 24896268 PMCID: PMC4045719 DOI: 10.1371/journal.pone.0098473] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Accepted: 05/02/2014] [Indexed: 11/18/2022] Open
Abstract
Despite aggressive therapies, including combinations of surgery, radiotherapy and chemotherapy, glioblastoma remains a highly aggressive brain cancer with the worst prognosis of any central nervous system disease. We have previously identified a neurofilament-derived cell-penetrating peptide, NFL-TBS.40-63, that specifically enters by endocytosis in glioblastoma cells, where it induces microtubule destruction and inhibits cell proliferation. Here, we explore the impact of NFL-TBS.40-63 peptide on the mitochondrial network and its functions by using global cell respiration, quantitative PCR analysis of the main actors directing mitochondrial biogenesis, western blot analysis of the oxidative phosphorylation (OXPHOS) subunits and confocal microscopy. We show that the internalized peptide disturbs mitochondrial and microtubule networks, interferes with mitochondrial dynamics and induces a rapid depletion of global cell respiration. This effect may be related to reduced expression of the NRF-1 transcription factor and of specific miRNAs, which may impact mitochondrial biogenesis, in regard to default mitochondrial mobility.
Collapse
Affiliation(s)
- Romain Rivalin
- Université d'Angers, Angers, France
- Laboratoire Neurobiologie & Transgenese, LNBT, UPRES EA-3143, Université d'Angers, Bâtiment IBS-IRIS, Angers, France
| | - Claire Lepinoux-Chambaud
- Université d'Angers, Angers, France
- Laboratoire Neurobiologie & Transgenese, LNBT, UPRES EA-3143, Université d'Angers, Bâtiment IBS-IRIS, Angers, France
| | - Joël Eyer
- Université d'Angers, Angers, France
- Laboratoire Neurobiologie & Transgenese, LNBT, UPRES EA-3143, Université d'Angers, Bâtiment IBS-IRIS, Angers, France
| | - Frédérique Savagner
- Université d'Angers, Angers, France
- Laboratoire Neurobiologie & Transgenese, LNBT, UPRES EA-3143, Université d'Angers, Bâtiment IBS-IRIS, Angers, France
- CHU Angers, Laboratoire de Biochimie, Angers, France
- * E-mail:
| |
Collapse
|
14
|
Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab 2012; 23:459-66. [PMID: 22817841 PMCID: PMC3580164 DOI: 10.1016/j.tem.2012.06.006] [Citation(s) in RCA: 568] [Impact Index Per Article: 47.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Revised: 06/15/2012] [Accepted: 06/19/2012] [Indexed: 02/06/2023]
Abstract
Gene regulatory factors encoded by the nuclear genome are essential for mitochondrial biogenesis and function. Some of these factors act exclusively within the mitochondria to regulate the control of mitochondrial transcription, translation, and other functions. Others govern the expression of nuclear genes required for mitochondrial metabolism and organelle biogenesis. The peroxisome proliferator-activated receptor γ coactivator-1 (PGC-1) family of transcriptional coactivators play a major role in transducing and integrating physiological signals governing metabolism, differentiation, and cell growth to the transcriptional machinery controlling mitochondrial functional capacity. Thus, the PGC-1 coactivators serve as a central component of the transcriptional regulatory circuitry that coordinately controls the energy-generating functions of mitochondria in accordance with the metabolic demands imposed by changing physiological conditions, senescence, and disease.
Collapse
Affiliation(s)
- Richard C Scarpulla
- Department of Cell and Molecular Biology, Northwestern University Medical School, Chicago, IL 60611, USA
| | | | | |
Collapse
|
15
|
Jaubert AM, Penot G, Niang F, Durant S, Forest C. Rapid nitration of adipocyte phosphoenolpyruvate carboxykinase by leptin reduces glyceroneogenesis and induces fatty acid release. PLoS One 2012; 7:e40650. [PMID: 22808220 PMCID: PMC3394747 DOI: 10.1371/journal.pone.0040650] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Accepted: 06/11/2012] [Indexed: 01/29/2023] Open
Abstract
Fatty acid (FA) release from white adipose tissue (WAT) is the result of the balance between triglyceride breakdown and FA re-esterification. The latter relies on the induction of cytosolic phosphoenolpyruvate carboxykinase (PEPCK-C), the key enzyme for glyceroneogenesis. We previously demonstrated that long-term (18 h) leptin treatment of rat epididymal WAT explants reduced glyceroneogenesis through nitric oxide (NO)-induced decrease in PEPCK-C expression. We investigated the effect of a short-term leptin treatment (2 h) on PEPCK-C expression and glyceroneogenesis in relation to NO production. We demonstrate that in WAT explants, leptin-induced NO synthase III (NOS III) phosphorylation was associated with reduced PEPCK-C level and glyceroneogenesis, leading to FA release, while PEPCK-C gene expression remained unaffected. These effects were absent in WAT explants from leptin receptor-deficient Zucker rat. Immunoprecipitation and western blot experiments showed that the leptin-induced decrease in PEPCK-C level was correlated with an increase in PEPCK-C nitration. All these effects were abolished by the NOS inhibitor Nω-nitro-L-arginine methyl ester and mimicked by the NO donor S-nitroso-N-acetyl-DL penicillamine. We propose a mechanism in which leptin activates NOS III and induces NO that nitrates PEPCK-C to reduce its level and glyceroneogenesis, therefore limiting FA re-esterification in WAT.
Collapse
Affiliation(s)
- Anne-Marie Jaubert
- Institut National de la Santé et de la Recherche Médicale UMR-S 747; Université Paris Descartes, Pharmacologie Toxicologie et Signalisation Cellulaire, Paris, France
- Département de Biochimie et de Biologie Moléculaire, Faculté de Médecine Paris-Ile de France-Ouest; Université de Versailles Saint-Quentin en Yvelines, Versailles, France
| | - Graziella Penot
- Institut National de la Santé et de la Recherche Médicale UMR-S 747; Université Paris Descartes, Pharmacologie Toxicologie et Signalisation Cellulaire, Paris, France
| | - Fatoumata Niang
- Institut National de la Santé et de la Recherche Médicale UMR-S 747; Université Paris Descartes, Pharmacologie Toxicologie et Signalisation Cellulaire, Paris, France
| | - Sylvie Durant
- Institut National de la Santé et de la Recherche Médicale UMR-S 747; Université Paris Descartes, Pharmacologie Toxicologie et Signalisation Cellulaire, Paris, France
| | - Claude Forest
- Institut National de la Santé et de la Recherche Médicale UMR-S 747; Université Paris Descartes, Pharmacologie Toxicologie et Signalisation Cellulaire, Paris, France
| |
Collapse
|
16
|
Joffin N, Niang F, Forest C, Jaubert AM. Is there NO help for leptin? Biochimie 2012; 94:2104-10. [PMID: 22750650 DOI: 10.1016/j.biochi.2012.06.017] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Accepted: 06/15/2012] [Indexed: 01/14/2023]
Abstract
Since the initial identification of leptin as the product of the ob gene in 1994, the signaling pathways by which this hormone alters cell physiology have been the subject of extensive investigations. The fact that leptin can induce nitric oxide (NO) production was first demonstrated in studies of the pituitary gland and pancreatic islets. A large number of additional studies further showed that this adipokine stimulates NO synthesis in multiple tissues. This review article discusses the role of leptin in NO production and its pathophysiological consequences. The role of this gaseous messenger in cell physiology depends on the cell type, the concentration of NO and the duration of exposure. It can be either a potent oxidant or a protector of cell integrity against the formation of reactive oxygen species. Leptin plays two opposing roles on arterial pressure. It exerts a hypertensive effect due to sympathetic activation and a vasorelaxant effect due to NO production. This adipokine acts via NO to produce pro-inflammatory factors in cartilage pathology, potentially contributing to an increased risk for osteoarthritis. Another well-documented role of leptin-induced NO, acting either directly or via the hypothalamus, concerns lipid metabolism in muscle and adipose tissue. In adipocytes, the direct and rapid action of leptin is to activate the nitric oxide synthase III, which favors lipolysis. In contrast, in the long-term, leptin reduces lipolysis. However, both in the short-term and in the long-term, glyceroneogenesis and its key enzyme, the cytosolic phosphoenolpyruvatecarboxykinase (PEPCK-C), are down-regulated by the adipokine, thus favoring fatty acid release. Hence, leptin-induced NO production plays a crucial role in fatty acid metabolism in adipose tissue. The resulting effects are to prevent lipid storage and to improve energy expenditure, with possible improvements of the obese state and its associated diseases.
Collapse
Affiliation(s)
- Nolwenn Joffin
- Institut National de la Santé et de la Recherche Médicale UMR-S 747, Université Paris Descartes, Pharmacologie Toxicologie et Signalisation Cellulaire, 45 rue des Saints Pères, 75006 Paris, France
| | | | | | | |
Collapse
|
17
|
He X, Sun C, Wang F, Shan A, Guo T, Gu W, Cui B, Ning G. Peri-implantation lethality in mice lacking the PGC-1-related coactivator protein. Dev Dyn 2012; 241:975-83. [PMID: 22411706 DOI: 10.1002/dvdy.23769] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/23/2012] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Members of the PPARγ coactivator-1 (PGC-1) family are central transcriptional coactivators that regulate cell metabolic processes ranging from mitochondrial biogenesis to oxidative respiration. PGC-1-related coactivator (PPRC1 or PRC), initially identified as a member of the PGC-1 family, is believed to regulate mitochondria biogenesis, respiration pathways, and cell proliferation. However, its physiological role is not clearly understood. Here, we investigate the biological functions of PPRC1 in vivo using PPRC1 deficient mice generated by gene targeting. RESULTS Homozygous deficient PPRC1 mice failed to form egg cylinders and died after implantation but before embryonic day 6.5, whereas mice heterozygous for PPRC1 were viable, fertile and indistinguishable from their wild-type littermates. Furthermore, PPRC1 mRNA was expressed at the embryonic stage before implantation and was rapidly up-regulated during the first day of embryoid body formation. The PPRC1 mRNA was then subsequently down-regulated, although its precise function at this stage of development was unclear. CONCLUSIONS This is the first study to suggest a nonredundant role for PPRC1 in mouse early embryonic development.
Collapse
Affiliation(s)
- Xin He
- Laboratory of Endocrine and Metabolic Diseases, Institute of Health Sciences, Shanghai Institutes for Biological Sciences, Shanghai, P. R. China
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Scarpulla RC. Nucleus-encoded regulators of mitochondrial function: integration of respiratory chain expression, nutrient sensing and metabolic stress. BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS 2011; 1819:1088-97. [PMID: 22080153 DOI: 10.1016/j.bbagrm.2011.10.011] [Citation(s) in RCA: 91] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/06/2011] [Accepted: 10/28/2011] [Indexed: 12/23/2022]
Abstract
Nucleus-encoded regulatory factors are major contributors to mitochondrial biogenesis and function. Several act within the organelle to regulate mitochondrial transcription and translation while others direct the expression of nuclear genes encoding the respiratory chain and other oxidative functions. Loss-of-function studies for many of these factors reveal a wide spectrum of phenotypes. These range from embryonic lethality and severe respiratory chain deficiency to relatively mild mitochondrial defects seen only under conditions of physiological stress. The PGC-1 family of regulated coactivators (PGC-1α, PGC-1β and PRC) plays an important integrative role through their interactions with transcription factors (NRF-1, NRF-2, ERRα, CREB, YY1 and others) that control respiratory gene expression. In addition, recent evidence suggests that PGC-1 coactivators may balance the cellular response to oxidant stress by promoting a pro-oxidant environment or by orchestrating an inflammatory response to severe metabolic stress. These pathways may serve as essential links between the energy generating functions of mitochondria and the cellular REDOX environment associated with longevity, senescence and disease. This article is part of a Special Issue entitled: Mitochondrial Gene Expression.
Collapse
Affiliation(s)
- Richard C Scarpulla
- Department of Cell and Molecular Biology, Northwestern Medical School, Chicago, IL 60611, USA.
| |
Collapse
|
19
|
Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, Rosenwald A, Jack A, Sundstrom C, Cogliatti S, Trougouboff P, Boudova L, Ysebaert L, Soulier J, Chevalier C, Bron D, Schmitz N, Gaulard P, Houlgatte R, Gisselbrecht C. The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. J Clin Oncol 2011; 29:4079-87. [PMID: 21947824 DOI: 10.1200/jco.2011.35.4423] [Citation(s) in RCA: 199] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Purpose To evaluate the prognostic value of the cell of origin (COO) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBLC), prospectively treated by rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) versus rituximab, ifosfamide, carboplatin, and etoposide and followed by intensive therapy plus autologous stem-cell transplantation on the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) trial. Patients and Methods Among the 396 patients included on the trial, histologic material was available for a total of 249 patients at diagnosis (n = 189 patients) and/or at relapse (n = 147 patients), which included 87 matched pairs. The patient data were analyzed by immunochemistry for CD10, BCL6, MUM1, FOXP1, and BCL2 expression and by fluorescent in situ hybridization for BCL2, BCL6 and c-MYC breakpoints. The correlation with survival data was performed by using the log-rank test and the Cox model. Results Characteristics of immunophenotype and chromosomal abnormalities were statistically highly concordant in the matched biopsies. In univariate analysis, the presence of c-MYC gene rearrangement was the only parameter to be significantly correlated with a worse progression-free survival (PFS; P = .02) and a worse overall survival (P = .04). When treatment interaction was tested, the germinal center B (GCB) –like DLBCL that was based on the algorithm by Hans was significantly associated with a better PFS in the R-DHAP arm. In multivariate analysis, independent prognostic relevance was found for the GCB/non-GCB the Hans phenotype interaction treatment (P = .04), prior rituximab exposure (P = .0052), secondary age-adjusted International Prognostic Index (P = .039), and FoxP1 expression (P = .047). Confirmation was obtained by gene expression profiling in a subset of 39 patients. Conclusion COO remains a major and independent factor in relapsed/refractory DLBCL, with a better response to R-DHAP in GCB-like DLBCL. This needs confirmation by a prospective study.
Collapse
Affiliation(s)
- Catherine Thieblemont
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Josette Briere
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Nicolas Mounier
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Hans-Ullrich Voelker
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Wendy Cuccuini
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Edouard Hirchaud
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Andreas Rosenwald
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Andrew Jack
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Christer Sundstrom
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Sergio Cogliatti
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Philippe Trougouboff
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Ludmila Boudova
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Loic Ysebaert
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Jean Soulier
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Catherine Chevalier
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Dominique Bron
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Norbert Schmitz
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Philippe Gaulard
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Remi Houlgatte
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| | - Christian Gisselbrecht
- Catherine Thieblemont, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Hematology; Catherine Thieblemont, Josette Briere, INSERM U728, Institut Universitaire d'hématologie, Paris VII; Catherine Thieblemont, Josette Briere, Nicolas Mounier, Philippe Gaulard, Christian Gisselbrecht, Groupe d'Etude des Lymphomes de l'Adulte; Josette Briere, Assistance Publique-Hôpitaux de Paris, Hôpital Saint Louis, Anatomie Pathologie; Wendy Cuccuini, Jean Soulier, Assistance Publique-Hôpitaux de Paris, Hôpital
| |
Collapse
|
20
|
Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. BIOCHIMICA ET BIOPHYSICA ACTA 2011; 1813:1269-78. [PMID: 20933024 PMCID: PMC3035754 DOI: 10.1016/j.bbamcr.2010.09.019] [Citation(s) in RCA: 838] [Impact Index Per Article: 64.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2010] [Revised: 09/14/2010] [Accepted: 09/27/2010] [Indexed: 12/23/2022]
Abstract
The PGC-1 family of regulated coactivators, consisting of PGC-1α, PGC-1β and PRC, plays a central role in a regulatory network governing the transcriptional control of mitochondrial biogenesis and respiratory function. These coactivators target multiple transcription factors including NRF-1, NRF-2 and the orphan nuclear hormone receptor, ERRα, among others. In addition, they themselves are the targets of coactivator and co-repressor complexes that regulate gene expression through chromatin remodeling. The expression of PGC-1 family members is modulated by extracellular signals controlling metabolism, differentiation or cell growth and in some cases their activities are known to be regulated by post-translational modification by the energy sensors, AMPK and SIRT1. Recent gene knockout and silencing studies of many members of the PGC-1 network have revealed phenotypes of wide ranging severity suggestive of complex compensatory interactions or broadly integrative functions that are not exclusive to mitochondrial biogenesis. The results point to a central role for the PGC-1 family in integrating mitochondrial biogenesis and energy production with many diverse cellular functions. This article is part of a Special Issue entitled: Mitochondria and Cardioprotection.
Collapse
Affiliation(s)
- Richard C Scarpulla
- Department of Cell and Molecular Biology, Northwestern Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA.
| |
Collapse
|
21
|
Le Pennec S, Mirebeau-Prunier D, Boutet-Bouzamondo N, Jacques C, Guillotin D, Lauret E, Houlgatte R, Malthièry Y, Savagner F. Nitric oxide and calcium participate in the fine regulation of mitochondrial biogenesis in follicular thyroid carcinoma cells. J Biol Chem 2011; 286:18229-39. [PMID: 21454643 PMCID: PMC3093895 DOI: 10.1074/jbc.m110.217521] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2010] [Revised: 03/29/2011] [Indexed: 11/06/2022] Open
Abstract
Members of the peroxisome proliferator-activated receptor γ coactivator-1 family (i.e. PGC-1α, PGC-1β, and the PGC-1-related coactivator (PRC)) are key regulators of mitochondrial biogenesis and function. These regulators serve as mediators between environmental or endogenous signals and the transcriptional machinery governing mitochondrial biogenesis. The FTC-133 and RO82 W-1 follicular thyroid carcinoma cell lines, which present significantly different numbers of mitochondria, metabolic mechanisms, and expression levels of PRC and PGC-1α, may employ retrograde signaling in response to respiratory dysfunction. Nitric oxide (NO) and calcium have been hypothesized to participate in this activity. We investigated the effects of the S-nitroso-N-acetyl-DL-penicillamine-NO donor, on the expression of genes involved in mitochondrial biogenesis and cellular metabolic functions in FTC-133 and RO82 W-1 cells by measuring lactate dehydrogenase and cytochrome c oxidase (COX) activities. We studied the action of ionomycin and 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl ester (BAPTA/AM) (i.e. a calcium ionophore and a cytosolic calcium chelator) on whole genome expression and mitochondrial biogenesis in RO82 W-1 cells. COX activity and the dynamics of endoplasmic reticulum and mitochondrial networks were analyzed in regard to calcium-modulating treatments. In the FTC-133 and RO82 W-1 cells, the mitochondrial biogenesis induced by NO was mainly related to PRC expression as a retrograde mitochondrial signaling. Ionomycin diminished COX activity and negatively regulated PRC-mediated mitochondrial biogenesis in RO82 W-1 cells, whereas BAPTA/AM produced the opposite effects with a reorganization of the mitochondrial network. This is the first demonstration that NO and calcium regulate mitochondrial biogenesis through the PRC pathway in thyroid cell lines.
Collapse
Affiliation(s)
| | - Delphine Mirebeau-Prunier
- From INSERM UMR694
- Université d'Angers, and
- Laboratoire de Biochimie, Centre Hospitalier Universitaire d'Angers, F-49033 Angers, France
| | | | | | | | | | - Rémi Houlgatte
- INSERM UMR915, l'Institut du Thorax, F-44007 Nantes, France, and
- Université de Nantes, F-44035 Nantes, France
| | - Yves Malthièry
- From INSERM UMR694
- Université d'Angers, and
- Laboratoire de Biochimie, Centre Hospitalier Universitaire d'Angers, F-49033 Angers, France
| | - Frédérique Savagner
- From INSERM UMR694
- Université d'Angers, and
- Laboratoire de Biochimie, Centre Hospitalier Universitaire d'Angers, F-49033 Angers, France
- INSERM UMR915, l'Institut du Thorax, F-44007 Nantes, France, and
| |
Collapse
|
22
|
Multi-site control and regulation of mitochondrial energy production. BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS 2010; 1797:698-709. [PMID: 20226160 DOI: 10.1016/j.bbabio.2010.02.030] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/09/2009] [Revised: 02/19/2010] [Accepted: 02/24/2010] [Indexed: 12/21/2022]
Abstract
With the extraordinary progress of mitochondrial science and cell biology, novel biochemical pathways have emerged as strategic points of bioenergetic regulation and control. They include mitochondrial fusion, fission and organellar motility along microtubules and microfilaments (mitochondrial dynamics), mitochondrial turnover (biogenesis and degradation), and mitochondrial phospholipids synthesis. Yet, much is still unknown about the mutual interaction between mitochondrial energy state, biogenesis, dynamics and degradation. Meanwhile, clinical research into metabolic abnormalities in tumors as diverse as renal carcinoma, glioblastomas, paragangliomas or skin leiomyomata, has designated new genes, oncogenes and oncometabolites involved in the regulation of cellular and mitochondrial energy production. Furthermore, the examination of rare neurological diseases such as Charcot-Marie Tooth type 2a, Autosomal Dominant Optic Atrophy, Lethal Defect of Mitochondrial and Peroxisomal Fission, or Spastic Paraplegia suggested involvement of MFN2, OPA1/3, DRP1 or Paraplegin, in the auxiliary control of mitochondrial energy production. Lastly, advances in the understanding of mitochondrial apoptosis have suggested a supplementary role for Bcl2 or Bax in the regulation of mitochondrial respiration and dynamics, which has fostered the investigation of alternative mechanisms of energy regulation. In this review, we discuss the regulatory mechanisms of cellular and mitochondrial energy production, and we emphasize the importance of the study of rare neurological diseases in addition to more common disorders such as cancer, for the fundamental understanding of cellular and mitochondrial energy production.
Collapse
|